Exactly what was a lie in the shareholder update?
PharmStar is currently in negotiations with three different funding groups for full funding to get into production. These talks are very promising.
PharmStar is in discussions with another pharmaceutical company to joint venture synergistic products.
PharmStar has now fully developed line extensions to Aquaprin, including Aquaprin Cough & Cold, Aquaprin Menstrual, Aquaprin Sinus, Aquaprin Allergy, Aquaprin Children and Teenagers.
PharmStar is now evaluating a sublingual fast dissolving tablet.
PharmStar is in discussions with two additional doctors for positions on our medical advisory board. PharmStar has made three tour presentations. Since we have not had a positive response from these meetings, we are considering ending this program since the promised funding for this tour did not occur.
PharmStar is in discussions with a new Public Relations Firm with an agreement almost completed.
News 
Market Data 
Discover 
